Search results for: 'pace pharmaceutical'

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

The research service aims to analyse and assess the global generics pharmaceutical market, map the key trends and dynamics shaping the industry sector and provide strategic recommendations for the success of the market participants. With several key blockbuster drugs losing patent protection and new healthcare reforms being introduced by the Govern...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

20 Jun 2017  |  North America  |  Market Research

Transformation and Growth Opportunities in the US Next-Generation Sequencing Informatics Market

Pharmaceutical and Molecular Diagnostics Segments to Lead Revenue Growth

Infographics

×

Frost & Sullivan expects strong demand for commercial application-focused solutions to drive new investments in the development of tools and technologies, and will also result in consolidation of the US next-generation sequencing informatics market. Changing customer requirements and intense competition will drive the transformation. As companies l...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

The overall objective of this study was to provide contract manufacturing organizations (CMOs) a sound basis for formulating an effective strategy to compete in the market, including areas of opportunities and threats. As far as the market dynamics and CMO selection are concerned, overall satisfaction and likelihood of contract renewal are in the 4...

Excipients have been a part of the pharmaceutical industry, and their demand is expected to increase during the forecast period. This is owing to their ability to perform various functions such as improving the API stability, modifying drug release, and taste masking. Expanding patient base, coupled with the need to develop cost-effective drugs, ha...

21 Dec 2016  |  Africa  |  Market Research

African Pharmaceuticals Market, Forecast to 2020

Assessing Market Potential with a Focus on Kenya and Nigeria

Infographics

×

The pharmaceuticals market in Africa is expected to reach a business opportunity of $45 billion in 2020, propelled by a convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic lifestyle diseases. The tropical climate of Africa makes the continent the largest re...